Russia's OnkoMaks Biotech Passes Prelinical Trials For Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Russian biotech OnkoMaks has completed preclinical testing of its first product, a targeted drug to prevent tumor growth in renal cell carcinoma